Related Experiment Video
Updated: Jun 9, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative
Louis Talay1, Matt Vickers2, Sarah Fuller2
1Faculty of Arts and Social Sciences, University of Sydney, Sydney, NSW 2050, Australia.
Healthcare (Basel, Switzerland)
|October 25, 2024
Summary
Prescribing errors in digital weight loss services using Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were analyzed. Most errors involved inadequate counseling and contraindication checks, particularly in patients with higher BMIs.
Area of Science:
- Pharmacovigilance
- Digital Health
- Obesity Medicine
Background:
- Digital weight loss services (DWLSs) utilizing Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise for obesity management.
- Concerns exist regarding the prescribing safety of these novel digital health interventions.
- Previous research on electronic prescribing safety was limited to traditional healthcare settings.
Purpose of the Study:
- To investigate the incidence and nature of prescribing errors in a large Australian GLP-1 RA-supported DWLS.
- To identify specific types of errors and patient demographics associated with prescribing inaccuracies.
Main Methods:
- Retrospective analysis of 37,323 GLP-1 RA prescriptions over a 6-month period in 2023.
- Utilized multiple auditing methods, including automated queries, to detect prescribing errors.
- Examined patient characteristics, focusing on body mass index (BMI) categories.
Main Results:
- A total of 1654 (4.4%) prescriptions contained errors.
- The most common errors were insufficient safety counseling (49.15%) and inadequate contraindication investigations (30.29%).
- Patients in the highest BMI category (40+ kg/m² ) were disproportionately represented in error data.
Conclusions:
- The study provides critical data on the prescribing safety of GLP-1 RA-supported DWLSs.
- Highlights the need for improved patient counseling and pre-treatment assessments in digital obesity management.
- Identifies high-BMI patients as a population requiring focused safety attention within these services.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:23Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:16Insulin: Dosing Regimen and Adverse Effects
148
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
148
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176